生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

未开盘 05-21 16:00:00

5,263.189

+72.418

+1.40%

最高5,380.148	最低5,191.586	成交量1.82亿
今开5,191.586	昨收5,190.771	日振幅3.63%
总市值0.00	流通市值0.00	总股本0.00
成交额66.12亿	换手率--	流通股本0.00
市净率5.553088	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5263.189,"timestamp":1779350893051,"preClose":5190.771,"halted":0,"volume":181647068,"delay":0,"changeRate":0.013951,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":72.417969,"latestTime":"05-21 16:00:00","open":5191.586,"high":5380.1484,"low":5191.586,"amount":6612166813.5,"amplitude":0.036326,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779413400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1779327000000,1779336000000],[1779339600000,1779350400000]],"pbRate":5.553088,"peRate":-495.77441,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161/tweets","defaultTab":"tweets","newsList":[{"id":"2637051332","title":"迈威生物（688062）披露9MW2821在ASCO年会报告最新临床数据，5月21日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637051332","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637051332?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:38","pubTimestamp":1779374294,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，迈威生物报收于33.48元，较前一交易日上涨1.09%，最新总市值为149.57亿元。该股当日开盘33.25元，最高35.07元，最低33.25元，成交额达3.61亿元，换手率为5.18%。近日，迈威生物发布自愿披露公告，宣布其自主研发的靶向Nectin-4 ADC药物9MW2821在2026年美国临床肿瘤学会年会上，将以口头报告和壁报形式展示最新临床数据。两项研究均未发现新的安全性信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637318303","title":"翰思艾泰-B(03378)5月21日耗资约67.47万港元回购2.31万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637318303","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637318303?lang=zh_cn&edition=full","pubTime":"2026-05-21 21:20","pubTimestamp":1779369657,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B(03378)公布，2026年5月21日耗资约67.47万港元回购2.31万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1173","03378","BK1161","BK1535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637367983","title":"加科思-B(01167)5月21日斥资46.3万港元回购8.73万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637367983","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637367983?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:55","pubTimestamp":1779368145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年5月21日，该公司斥资46.3万港元回购8.73万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01167","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637336908","title":"荃信生物-B(02509)：QX001S(乌司奴单抗注射液)用于克罗恩病的上市许可申请和补充申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336908","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637336908?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:44","pubTimestamp":1779367499,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，近日，中美华东收到国家药品监督管理局(NMPA)核准签发的《药品注册证书》及《药品补充申请批准通知书》，乌司奴单抗注射液(静脉输注)(商品名：赛捷宁®)和乌司奴单抗注射液(商品名：赛乐信®，研发代码：(QX001S/HDM3001-2))用于克罗恩病的上市许可申请和补充申请获得批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168923366","title":"荃信生物-B - 中每华东QX001s（乌司奴单抗注射液）获克罗恩病适应症批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1168923366","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168923366?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:44","pubTimestamp":1779367459,"startTime":"0","endTime":"0","summary":"荃信生物-B宣布，其与中每华东联合开发的QX001s（乌司奴单抗注射液）已正式获得用于治疗克罗恩病的适应症批准。这一进展标志着该生物类似药在自身免疫性疾病治疗领域取得了重要突破，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637336990","title":"思路迪医药股份(01244)：恩维达®非小细胞肺癌新辅助╱辅助治疗III期临床研究提前完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336990","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637336990?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:43","pubTimestamp":1779367407,"startTime":"0","endTime":"0","summary":"智通财经APP讯，思路迪医药股份 发布公告，本公司与康宁杰瑞生物制药共同开发的恩维达用于可切除非小细胞肺癌患者新辅助╱辅助治疗的随机、对照、双盲、多中心III期临床研究已提前完成入组。本次III期临床研究由天津医科大学肿瘤医院王长利教授担任主要研究者，在全国约60家临床研究中心开展，计划入组约390例可切除III期非小细胞肺癌患者，实际入组人数符合研究方案要求，已提前完成入组工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","BK4134","01244"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637433604","title":"青海湟中全域推广中（藏）医药康养文化 让传统医药可触可享","url":"https://stock-news.laohu8.com/highlight/detail?id=2637433604","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637433604?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:42","pubTimestamp":1779367320,"startTime":"0","endTime":"0","summary":"中新网西宁5月21日电 5月21日，青海省西宁市湟中区首届中(藏)医药康养文化推广活动在湟中区中医院启幕，让传统医药文化可感、可触、可享。此前，《中华医藏·藏医药卷》成果发布会在北京举行。作为河湟文化核心发源地，湟中区中(藏)医药传承历史悠久、民众根基深厚。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-21/doc-inhyshrf6355481.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-21/doc-inhyshrf6355481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159938","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637872380","title":"和铂医药-B(02142)5月21日斥资238.46万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637872380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637872380?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:59","pubTimestamp":1779361187,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年5月21日该公司斥资238.46万港元回购20万股，回购价格为每股11.70-12.19港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637387686","title":"君实生物：特瑞普利单抗注射液第13项适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2637387686","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637387686?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:36","pubTimestamp":1779359760,"startTime":"0","endTime":"0","summary":"5月21日，君实生物（688180/01877）发布公告，近日公司收到《药品注册证书》，其特瑞普利单抗（商品名：拓益?）联合维迪西妥单抗用于HER2表达的局部晚期或转移性尿路上皮癌患者的新适应症上市申请获得批准，这是特瑞普利单抗注射液在中国内地获批的第13项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605213745358513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","01877","BK1515","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198470954","title":"和黄医药与信达生物联合宣布：爱优特®（呋喹替尼）联合达伯舒®（信迪利单抗注射液）获NMPA批准用于治疗局部晚期或转移性肾细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1198470954","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198470954?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:02","pubTimestamp":1779357741,"startTime":"0","endTime":"0","summary":"和黄医药与信达生物今日共同发布公告，宣布其合作开发的联合疗法——爱优特®（呋喹替尼）与达伯舒®（信迪利单抗注射液）——已正式获得中国国家药品监督管理局的上市批准。该联合疗法获批用于治疗局部晚期或转移性肾细胞癌患者，为这一领域的临床治疗提供了新的重要选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU2488822045.USD","LU2328871848.SGD","BK1191","LU2097828631.EUR","00013","LU1969619763.USD","LU0502904849.HKD","LU2097828474.EUR","LU2242644610.SGD","LU0455707207.USD","01801","BK1589","BK1583","LU2097828557.USD","BK1161","BK1587","HK0000165453.HKD","BK1588","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637389179","title":"康宁杰瑞制药-B(09966)因期权获行使而发行8.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637389179","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637389179?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:32","pubTimestamp":1779355924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年5月21日，该公司因于2020年5月25日采纳及2024年6月12日修订的首次公开发售后购股权计划下行使期权而发行8.8万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637389898","title":"迈威生物(688062.SH)：9MW2821将在2026年美国临床肿瘤学会(ASCO)公布最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2637389898","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637389898?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:17","pubTimestamp":1779355058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，公司将在2026年5月29日-6 月2日于芝加哥举行的2026年美国临床肿瘤学会年会中，以口头报告形式公布靶向Nectin-4ADC创新药9MW2821 联合特瑞普利单抗用于局部晚期或转移性尿路上皮癌的Ib/II 期临床研究数据，以壁报形式公布9MW2821联合特瑞普利单抗用于围手术期肌层浸润性膀胱癌的II期临床研究数据。9MW2821给药后，可与肿瘤细胞表面的Nectin-4结合并进入细胞，通过酶解作用，定向释放细胞毒素，从而实现对肿瘤的精准杀伤。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","02493","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637860753","title":"复宏汉霖(02696)自主研发的注射用HLX48用于晚期/转移性实体瘤治疗的1期临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2637860753","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637860753?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:15","pubTimestamp":1779354954,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，近日，公司自主研发的注射用HLX48 用于晚期/转移性实体瘤治疗的1期临床试验申请获国家药品监督管理局批准。因此，HLX48有望实现靶向治疗与免疫调节的双重增效，抑制肿瘤生长并兼具良好安全性。临床前研究显示，HLX48抗肿瘤疗效及安全性良好，其有望获得临床获益。2026年5月，HLX48用于晚期/转移性实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局的临床试验备案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)自主研发的注射用HLX48用于晚期/转移性实体瘤治疗的1期临床试验申请获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","02696","HK0000306701.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125498263","title":"复宏汉霖获NMPA批准开展HLX48用于晚期/转移性实体瘤的I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1125498263","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125498263?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:15","pubTimestamp":1779354912,"startTime":"0","endTime":"0","summary":"复宏汉霖宣布，其创新药HLX48已获得中国国家药品监督管理局的临床试验默示许可，将针对晚期或转移性实体瘤患者开展I期临床研究。该批准标志着公司在肿瘤治疗领域的研发管线取得又一重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306701.USD","HK0000320223.HKD","02696","HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637865503","title":"信达生物(01801)：达伯舒® 联合爱优特® 获中国国家药监局批准用于治疗晚期或转移性肾细胞癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2637865503","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637865503?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:56","pubTimestamp":1779353809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 公布，达伯舒 和爱优特 的联合疗法的新药上市申请获中国国家药品监督管理局批准，用于治疗既往接受血管内皮生长因子受体-酪氨酸激酶抑制剂治疗失败且一线未接受程序性死亡受体-1或程序性死亡配体-1抑制剂的局部晚期或转移性肾细胞癌患者。此项批准是基于FRUSICA-2研究的数据支持。此次获批对中国晚期肾细胞癌患者而言是一个重要的里程碑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物(01801)：达伯舒® 联合爱优特® 获中国国家药监局批准用于治疗晚期或转移性肾细胞癌患者","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","LU0502904849.HKD","LU2328871848.SGD","LU2097828557.USD","LU2097828631.EUR","BK1583","BK1161","LU0455707207.USD","LU2242644610.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828714.EUR","BK1589","01801","LU2097828805.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637838567","title":"5月21日诺诚健华涨5.55%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637838567","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637838567?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:36","pubTimestamp":1779352598,"startTime":"0","endTime":"0","summary":"证券之星消息，5月21日诺诚健华涨5.55%，收盘报25.85元，换手率7.97%，成交量21.38万手，成交额5.55亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为31.86亿元，最新净值3.0059，较上一交易日上涨0.07%，近一年上涨6.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100030556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09969","688428","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637383065","title":"5月21日司太立跌6.25%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637383065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637383065?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:28","pubTimestamp":1779352119,"startTime":"0","endTime":"0","summary":"证券之星消息，5月21日司太立跌6.25%，收盘报12.89元，换手率14.24%，成交量62.42万手，成交额8.31亿元。重仓司太立的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家；过去90天内机构目标均价为14.08。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.46亿元，最新净值0.5976，较上一交易日下跌0.83%，近一年上涨14.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100030325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","159938","BK0239","BK1161","603520","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637262383","title":"港股全日高开低走 恒科指数收盘跌超2% 百度集团-SW(09888)挫逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637262383","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637262383?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:19","pubTimestamp":1779351591,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股全日高开低走且全线翻绿，午后跌幅进一步扩大，恒科指数跌幅超2%。截至收盘，恒生指数报25383点，下跌1.03%；国企指数下跌0.51%；恒生科技指数下跌2.15%。个股方面，网易-S午后跌幅急剧扩大，最终收跌4.82%。万国数据-SW全天走软，收跌13.25%。高盛预计，随著新订单交付，投资组合经调整毛利收益率将维持在10%至11%区间。该行维持对万国数据的“买入”评级，给予H股12个月目标价54港元，万国数据美股目标价55美元。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ZjI3MDQ3NzQxODE1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjI3MDQ3NzQxODE1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981980","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09067","SG9999014674.SGD","LU1211504680.USD","BK4077","LU1719994722.HKD","LU0762540952.USD","LU0211977185.USD","LU2401740654.USD","LU1115378108.SGD","BK1095","GDS","LU0543330566.HKD","09999","LU0210526637.USD","GB00BDT5M118.USD","LU0640798160.USD","BK1521","HSTECH","LU0043850808.USD","BK4552","LU0039217434.USD","LU1328615791.USD","LU0708995583.HKD","09698","LU0163747925.USD","LU0502904849.HKD","89888","LU1015430645.USD","LU2041044095.USD","BK4614","LU1770034418.SGD","LU0173614495.USD","LU1188198961.HKD","00005","LU0456827905.SGD","LU0359202008.SGD","BK1608","LU0823426308.USD","LU1481107354.HKD","LU2092937221.SGD","SG9999002828.SGD","BK4548","LU0856984785.SGD","LU2097828631.EUR","HK0000306701.USD","LU1048588211.SGD","LU0315179316.USD","LU1892829315.USD","BK4602","LU0997587240.USD","LU1720050803.USD","BK4574","IE00B0JY6N72.USD","07552","BK1589","BK4587","LU0320764599.SGD","BK1504","BK4514","BK4543","LU2380233275.USD","LU0997586606.USD","LU2097828805.USD","09088","BK1609","LU1863844749.USD","LU0821914370.USD","IE0034224299.USD","LU2476274308.USD","LU0612318971.USD","LU0417516738.SGD","LU0593848301.USD","BK4526","BK1161","LU1794554557.SGD","LU1863844665.USD","LU0531971595.HKD","LU0359201612.USD","LU0654597011.USD","LU0823426480.USD","LU0612318385.USD","03067","LU0052750758.USD","BK1590","LU0051755006.USD","LU0164865239.USD","LU0819121731.USD","LU0385154629.USD","BK1591","LU0831093199.SGD","LU2242646821.SGD","HK0000320264.USD","LU0762542818.HKD","LU2242646235.USD","HK0000165453.HKD","LU0244354667.USD","LU0348825331.USD","LU2298321311.HKD","HK0000306685.HKD","HSI","LU0417516902.SGD","HSBC","LU0550127509.SGD","LU0164880469.USD","LU0572944931.SGD","LU0072462343.USD","03417","LU0326950275.SGD","LU0149721374.USD","LU1430597077.USD","LU2039709279.SGD","BIDG","LU0471298777.SGD","LU1989763427.SGD","LU2360106947.USD","LU1303224171.USD","LU1119994140.HKD","LU0455707207.USD","IE00B29SXG58.USD","KSTmain","02837","LU2488822045.USD","03033","03088","LU2242652126.USD","LU1989763690.USD","81024","NTES","BK4612","LU1969619763.USD","LU2097828474.EUR","03032","LU2242644610.SGD","LU0197773673.USD","LU0307460666.USD","BK1583","BK4585","HK0000320223.HKD","LU1920062954.HKD","LU1023057109.AUD","LU0630378429.USD","BK1587","LU0048578792.EUR","LU2097828557.USD","BK4504","LU0287142896.SGD","LU0348767384.USD","LU2328871848.SGD","LU1920063259.USD","BK4579","LU0359201885.HKD","LU0463099449.HKD","03423","LU0348766576.USD","09888","LU0575583348.USD","BK1575","LU1048596156.SGD","LU1831875114.USD","BK4535","LU2778985437.USD","BK1170","LU0630378692.HKD","LU0348735423.USD","LU0327786744.USD","LU0471298694.HKD","BK1610","LU0197773160.USD","LU0140636845.USD","BK1588","LU1251922891.USD","LU0229945570.USD","LU1803068623.USD","SG9999002463.SGD","LU0588546209.SGD","BK4531","LU0228367735.SGD","BK1615","BK4136","LU2360108059.USD","KBDU","BIDU","LU0762541174.USD","BK4588","LU2097828714.EUR","LU0871576103.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637388893","title":"5月21日昂利康（002940）涨停分析：业绩高增、创新药进展与宠物药放量驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2637388893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637388893?lang=zh_cn&edition=full","pubTime":"2026-05-21 15:33","pubTimestamp":1779348831,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康5月21日涨停收盘，收盘价45.65元。5月21日昂利康涨停的可能因素有：2025年归母净利润同比大增56.15%、扣非净利增78.82%，核心制剂业务营收增长超20%；定增11.2亿元获深交所受理，全部投向创新药ALK-N001Ⅰ期临床；富马酸伏诺拉生片获批双规格注册证书；宠物麻醉药批文落地且销量倍增；头孢全酶法工艺及阿莫西林技改强化原料药一体化能力。近5日资金流向一览见下表：该股为创新药，医药，化学原料药概念热股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100023617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239","159992","06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380754","title":"港股异动 | 信达生物(01801)反弹逾4% IBI3031完成临床登记 重磅布局TED精准治疗赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380754","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637380754?lang=zh_cn&edition=full","pubTime":"2026-05-21 14:54","pubTimestamp":1779346486,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物反弹逾4%，截至发稿，涨3.02%，报81.8港元，成交额7.35亿港元。消息面上，5月20日，药物临床试验登记与信息公示平台官网公示，信达生物正式登记一项I期临床研究，旨在评估IBI3031单次及多次给药在甲状腺眼病患者中的安全性、耐受性和药代动力学特征，这也是该药物启动的首个临床试验。作为全球首创的双靶点创新药物，IBI3031凭借差异化机制与更优给药潜力，有望突破现有治疗局限，为TED患者带来更高效、便捷的治疗新选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1161","LU2097828805.USD","LU2097828631.EUR","BK4588","HK0000165453.HKD","LU2097828557.USD","LU0455707207.USD","LU0502904849.HKD","LU2488822045.USD","BK4585","LU2328871848.SGD","01801","LU2097828474.EUR","LU2242644610.SGD","LU1969619763.USD","LU2097828714.EUR","VXUS","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.038},{"period":"1month","weight":-0.0416},{"period":"3month","weight":-0.0389},{"period":"6month","weight":0.0066},{"period":"1year","weight":0.0654},{"period":"ytd","weight":-0.0095}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}